retatrutide triple hormone receptor agonist metabolic obesity glp-1 gip glucagon phase 2 nejm 2023 Medscape The data just dropped —

This data from rodent studies has led to GLP-1RAs being contraindicated in patients with a personal or family history of MTC or with multiple endocrine neoplasia syndrome type 2

Impact of probiotic bacteria on respiratory allergy disorders

It is also possible that riboflavin exerts its antioxidant effect by reinforcing the effect of other antioxidants such as vitamin C ( Reference Rao and Bhat 29 )

This helps prevent the blood sugar spikes that drive insulin resistance over time

Hsieh MJ, Lee CH, Chueh HY, Chang GJ, Huang HY, Lin Y, Pang JS

Retatrutide (LY3437943), a Novel GIP/GLP-1/Glucagon Receptor TriagonistObesity, NAFLD, and T2D Phase 2 Trial Results In this medfyle Two phase II studies showed that the triple agonist retatrutide is associated with significant weight loss in obese patients and substantial improvement in glycemia control and significant weight loss in patients with T2D